School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China.
Beijing Scipromed Biotech Co., Ltd., Beijing, China.
IUBMB Life. 2024 Dec;76(12):1175-1185. doi: 10.1002/iub.2898. Epub 2024 Jul 24.
The utilization of anti-CD3/CD28 magnetic beads for T cell expansion in vitro has been investigated for adoptive cell transfer therapy. However, the impact of the CD3/CD28 antibody ratio on T cell differentiation and function remains incompletely elucidated. This study seeks to address this knowledge gap. To begin with, CD3 antibodies with a relatively low avidity for Jurkat cells (Kd = 13.55 nM) and CD28 antibodies with a relatively high avidity (Kd = 5.79 nM) were prepared. Afterwards, anti-CD3/CD28 antibodies with different mass ratios were attached to magnetic beads to examine the impacts of different antibody ratios on T cell capture, and proliferation. The research demonstrated that the most significant expansion of T cells was stimulated by the anti-CD3/CD28 magnetic beads with a mass ratio of 2:1 for CD3 antibodies and CD28 antibodies. Moreover, CD25 and PD1 expression of expanded T cells increased and then decreased, with lower CD25 and PD1 expression in the later stages of expansion indicating that T cells were not depleted. These T cells, which are massively expanded in vitro and have excellent expansion potential, can be infused back into the patient to treat tumor patients. This study shows that altering the ratio of anti-CD3/CD28 antibodies can control the strength of T cell stimulation, thereby leading to the improvement of T cell activation. This discovery can be utilized as a guide for the creation of other T cell stimulation approaches, which is beneficial for the further development of tumor immunotherapy technology.
抗 CD3/CD28 磁珠在体外用于 T 细胞扩增的应用已被研究用于过继细胞转移治疗。然而,CD3/CD28 抗体比例对 T 细胞分化和功能的影响仍不完全清楚。本研究旨在解决这一知识空白。首先,制备了对 Jurkat 细胞具有相对低亲和力的 CD3 抗体(Kd=13.55 nM)和具有相对高亲和力的 CD28 抗体(Kd=5.79 nM)。然后,将不同质量比的抗 CD3/CD28 抗体连接到磁珠上,以研究不同抗体比例对 T 细胞捕获和增殖的影响。研究表明,CD3 抗体和 CD28 抗体的质量比为 2:1 的抗 CD3/CD28 磁珠刺激 T 细胞的扩增效果最为显著。此外,扩增的 T 细胞的 CD25 和 PD1 表达增加,然后减少,在后期扩增阶段的 CD25 和 PD1 表达较低,表明 T 细胞未耗尽。这些在体外大量扩增且具有优异扩增潜力的 T 细胞可以回输给患者,用于治疗肿瘤患者。本研究表明,改变抗 CD3/CD28 抗体的比例可以控制 T 细胞刺激的强度,从而改善 T 细胞的激活。这一发现可以作为指导其他 T 细胞刺激方法的依据,有利于肿瘤免疫治疗技术的进一步发展。